These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rivaroxaban with or without aspirin for prevention of cardiovascular disease. Kruger PC; Eikelboom JW; Yusuf S Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127 [No Abstract] [Full Text] [Related]
3. VOYAGER PAD contributes to medical therapy for peripheral artery disease. Farber A J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822 [No Abstract] [Full Text] [Related]
4. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. Ambler GK; Nordanstig J; Behrendt CA; Twine CP Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837 [No Abstract] [Full Text] [Related]
5. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Fox KAA; Eikelboom JW; Anand SS; Bhatt DL; Bosch J; Connolly SJ; Harrington RA; Steg PG; Yusuf S Eur Heart J; 2019 May; 40(18):1466-1471. PubMed ID: 29945212 [No Abstract] [Full Text] [Related]
6. Thromboprophylaxis by rivaroxaban, aspirin, both, or placebo after hospitalization for medical illness. Tomkowski WZ; Davidson BL Thromb Res; 2019 Aug; 180():62-63. PubMed ID: 31226663 [No Abstract] [Full Text] [Related]
7. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. Hart RG; Sharma M; Mundl H; Kasner SE; Bangdiwala SI; Berkowitz SD; Swaminathan B; Lavados P; Wang Y; Wang Y; Davalos A; Shamalov N; Mikulik R; Cunha L; Lindgren A; Arauz A; Lang W; Czlonkowska A; Eckstein J; Gagliardi RJ; Amarenco P; Ameriso SF; Tatlisumak T; Veltkamp R; Hankey GJ; Toni D; Bereczki D; Uchiyama S; Ntaios G; Yoon BW; Brouns R; Endres M; Muir KW; Bornstein N; Ozturk S; O'Donnell MJ; De Vries Basson MM; Pare G; Pater C; Kirsch B; Sheridan P; Peters G; Weitz JI; Peacock WF; Shoamanesh A; Benavente OR; Joyner C; Themeles E; Connolly SJ; N Engl J Med; 2018 Jun; 378(23):2191-2201. PubMed ID: 29766772 [TBL] [Abstract][Full Text] [Related]
8. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Bhagirath VC; Eikelboom JW; Anand SS Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662 [TBL] [Abstract][Full Text] [Related]
9. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. Dangas GD; Tijssen JGP; Wöhrle J; Søndergaard L; Gilard M; Möllmann H; Makkar RR; Herrmann HC; Giustino G; Baldus S; De Backer O; Guimarães AHC; Gullestad L; Kini A; von Lewinski D; Mack M; Moreno R; Schäfer U; Seeger J; Tchétché D; Thomitzek K; Valgimigli M; Vranckx P; Welsh RC; Wildgoose P; Volkl AA; Zazula A; van Amsterdam RGM; Mehran R; Windecker S; N Engl J Med; 2020 Jan; 382(2):120-129. PubMed ID: 31733180 [TBL] [Abstract][Full Text] [Related]
10. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Prandoni P; Lensing AWA; Prins MH; Gebel M; Pap AF; Homering M; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Cohen AT; Davidson BL; van Bellen B; Verhamme P; Wells PS; Yuan Z; Levitan B; Weitz JI Thromb Res; 2018 Aug; 168():121-129. PubMed ID: 30064683 [TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. Ramacciotti E; Weitz JI Thromb Res; 2019 Dec; 184():44-49. PubMed ID: 31706067 [TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. Lamy A; Eikelboom J; Sheth T; Connolly S; Bosch J; Fox KAA; Zhu J; Lonn E; Dagenais G; Widimsky P; Branch KRH; Bhatt DL; Zheng Z; Straka Z; Dagenais F; Kong Y; Marsden T; Lee SF; Copland I; Yusuf S J Am Coll Cardiol; 2019 Jan; 73(2):121-130. PubMed ID: 30654882 [TBL] [Abstract][Full Text] [Related]
13. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638 [TBL] [Abstract][Full Text] [Related]
14. Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. Gibler WB Crit Pathw Cardiol; 2018 Jun; 17(2):53-68. PubMed ID: 29768312 [No Abstract] [Full Text] [Related]
15. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease. Camm AJ Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415 [TBL] [Abstract][Full Text] [Related]
16. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease? Boden WE; Bhatt DL Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448 [No Abstract] [Full Text] [Related]
17. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events. Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475 [No Abstract] [Full Text] [Related]
18. External applicability of the COMPASS trial: the Western Denmark Heart Registry. Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315 [TBL] [Abstract][Full Text] [Related]
19. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR; Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682 [TBL] [Abstract][Full Text] [Related]
20. Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. Hart RG; Veltkamp RC; Sheridan P; Sharma M; Kasner SE; Bangdiwala SI; Ntaios G; Shoamanesh A; Ameriso SF; Toni D; Czlonkowska A; Lindgren A; Hankey GJ; Perera KS; Shuaib A; Coutts SB; Gagliardi RJ; Berkowitz SD; Mundl H; Peters G; Connolly SJ; J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2273-2279. PubMed ID: 31160218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]